KAT2B and fatty liver disease: This observation is consistent with the results of a previous study in which liver‐specific ACLY down‐regulation in leptin receptor‐deficient db/db mice led to the inhibition of hepatic de novo lipogenesis and protection against hepatic steatosis.74 Therefore, in this case, approaches to reduce hepatic PCAF activity or expression could serve as potential therapeutic strategies for the treatment of fatty liver disease.